Shares of Synairgen plc (LON:SNG – Get Free Report) shot up 17.5% on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.50 ($0.06). 1,356,600 shares were traded during trading, an increase of 255% from the average session volume of 381,930 shares. The stock had previously closed at GBX 3.83 ($0.05).
Synairgen Trading Up 17.5 %
The business has a 50 day moving average of GBX 6.30 and a two-hundred day moving average of GBX 5.94. The firm has a market cap of £9.06 million, a P/E ratio of -76.60 and a beta of -2.23. The company has a current ratio of 6.77, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09.
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than Synairgen
- Trading Halts Explained
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Progress Software Stock Back in the Green After Beating Forecasts
- What is a Secondary Public Offering? What Investors Need to Know
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
